FDC Limited has announced the conclusion of inspection proceedings by the Maharashtra Goods & Service Tax Department at its corporate office in Mumbai. The pharmaceutical company informed stock exchanges on February 17, 2026, that the inspection concluded on February 16, 2026, at 23:55 hours, following the initial commencement on February 10, 2026.

Inspection Timeline and Conclusion

The GST Department had initiated inspection and search proceedings at FDC Limited's corporate office located at FDC House, Andheri West, Mumbai on February 10, 2026, at 1615 hours. The proceedings, conducted under sub-section (1) and sub-section (2) of Section 67 of the Maharashtra Goods & Service Tax Act, 2017, spanned approximately six days before reaching completion.

Compliance and Documentation

According to the company's disclosure made pursuant to SEBI Circular no. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024, FDC Limited provided all necessary documents, clarifications, and details as requested by the authorities. The company emphasized that no official document has been issued by the authorities regarding any violations or contraventions.

Impact Assessment

The company has confirmed that the concluded inspection has no material impact on its financial position, operations, or other business activities. This assessment remains consistent with the company's earlier disclosure when the inspection was initiated, where it had stated that business operations continued as usual during the inspection period.

Regulatory Compliance

FDC Limited made this disclosure under Regulation 30 of the SEBI Listing Obligations and Disclosure Requirements Regulations, 2015, following up on its initial intimation dated February 10, 2026. The disclosure was signed by Varsharani Katre, Company Secretary & Legal Head, demonstrating the company's commitment to maintaining transparency with stakeholders and regulatory compliance throughout the inspection process.

FDC Limited announced its Q3FY26 financial results alongside declaring an interim dividend of ₹5 per equity share for FY2025-26. The Board of Directors approved these decisions at their meeting held on February 5, 2026, with the record date for dividend payment set as February 11, 2026.

Financial Performance Overview

The company reported revenue from operations of ₹465 crores for Q3FY26, registering marginal growth of 0.1% year-over-year compared to ₹464 crores in Q3FY25. Despite flat revenue performance, FDC demonstrated operational efficiency improvements with enhanced profitability metrics.

Dividend Declaration and Corporate Actions

The Board approved an interim dividend of ₹5 per equity share of face value ₹1 each for FY2025-26, maintaining consistency with the previous year's interim dividend of ₹5 per share declared in November 2024. The record date for dividend eligibility has been fixed as Wednesday, February 11, 2026.

Exceptional Items Impact

The company recognized exceptional expenses of ₹2,079 lakhs during Q3FY26 due to the implementation of New Labour Codes effective November 21, 2025. This one-time impact relates to incremental employee benefit obligations arising from changes in wage definitions under the new regulatory framework.

Business Segment Performance

FDC's revenue performance varied across different business segments, with export formulations showing strong growth while domestic formulations faced headwinds.

Export Formulations delivered robust performance with ₹71 crores in sales, registering impressive growth of 55.0% year-over-year. The US business showed steady recovery with revenue from supplies reaching ₹43 crores during 9MFY26, reflecting 82.8% year-over-year growth driven by improved execution and demand momentum.